ClinicalTrials.gg
CompletedNCT04154072Updated Sep 19, 2024

A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease

A Phase 2 interventional study of NLY01 and Vehicle in Parkinson Disease, sponsored by Neuraly, Inc.. Completed at 61 sites in 2 countries. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Neuraly, Inc. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Feb 2023, 3 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
255
Allocation
Randomized
Ages
30 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,650 studies in Parkinson Disease with a site in United States — 305 open to participants now, 387 under way, 7 of them phase 3. Parkinson Disease · United States.

Enrollment
127th of 1,257
255 · median 36
Started
2020
with 89 others
Phase 2
234 of 1,650
25 open now
Registered
1,017th of 1,650
by date

Among the 1,650 studies in Parkinson Disease with a site in United States, this one is the 127th largest by enrollment of the 1,257 interventional ones that give a count, is one of 90 that started in 2020, is one of 234 in phase 2, and was the 1,017th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

305 of the 1,650 studies in Parkinson Disease with a site in United States are open now. Recruiting first, the newest first:

300 more — sign in →

All 305 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,650 studies in Parkinson Disease with a site in United States, or all of them as a file.
02

Study summary

This is a phase 2 study designed to assess the safety, tolerability and efficacy of NLY01 in subjects with early untreated Parkinson's disease (PD). Evidence suggests NLY01, a pegylated form of exenatide, may be beneficial in PD and is being developed as a potential treatment for neurodegenerative disorders.

03

Conditions studied

  • Parkinson Disease

Browse trials for

04

Who can participate

Ages eligible
30 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who are diagnosed with Parkinson's disease according to UK Parkinson's Disease Society Brain Bank Clinical Diagnostic criteria or Movement Disorder Society Research Criteria
  • Patients with Parkinson's disease according to protocol specified scale assessments
  • DaTscan consistent with diagnosis of Parkinson's Disease
  • Men or women 30 to 80 years of age

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of secondary or atypical parkinsonism
  • Prior use of dopaminergic treatment or MAO-B inhibitors for more than 28 days
  • Medical or recreational use of marijuana or THC-containing compounds within 3 months of screening visit
  • Pregnant or planning to become pregnant
  • Metabolic, surgical, psychiatric or laboratory abnormality that would interfere with study compliance or safety in the judgment of the investigator
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
255 participants (actual)

Study arms

  • Active comparator
    NLY01 (2.5 mg)

    NLY01 2.5 mg injection

    Drug: NLY01

  • Active comparator
    NLY01 (5.0 mg)

    NLY01 5.0 mg injection

    Drug: NLY01

  • Placebo comparator
    Vehicle

    inactive drug, injection

    Drug: Vehicle

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Unified Parkinson's Disease Rating Scale in combined score of Parts II and III from baseline to 36 weeks

    This is the Unified Parkinson's Disease Rating Scale assessment (MDS-UPDRS). The investigator will assess II and III components of the Unified Parkinson's Disease Rating Scale. The Unified Parkinson's Disease Rating Scale Part II assesses motor aspects of experiences of daily living. The Unified Parkinson's Disease Rating Scale Part III assesses motor signs of Parkinson's Disease. The Unified Parkinson's Disease Rating Scale is a widely used assessment to quantify the signs and symptoms of Parkinson's Disease. Each subscale has 0-4 ratings, where 0=normal, 1=slight, 2=mild, 3=moderate and 4=severe. The scale is completed by the investigator and scores are derived from clinician and subject input to allow the assessment of symptomatic worsening and improvement.

    Time frame: 36 weeks

07

Study locations

61 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • St. Joseph's Hospital and Medical Center - Barrow Neurological Institute
    Phoenix, Arizona 85013, United States
  • Movement Disorders Center
    Scottsdale, Arizona 85258, United States
  • Mayo Clinic Arizona, Mayo Clinic Scottsdale
    Scottsdale, Arizona 85259, United States
  • Banner Sun Health Research Institute
    Sun City, Arizona 85351, United States
  • University of Arkansas for Medical Sciences
    Little Rock, Arkansas 72205, United States
  • University of California, Irvine
    Irvine, California 92697, United States
  • Keck School of Medicine of USC/University of Southern California
    Los Angeles, California 90033, United States
  • University of California, Los Angeles, Center for Neurotherapeutics
    Los Angeles, California 90095, United States
  • SC3 Research
    Pasadena, California 91105, United States
  • University of California Davis Health
    Sacramento, California 95816, United States
  • University of California, San Francisco
    San Francisco, California 94143, United States
  • University of Colorado
    Denver, Colorado 80204, United States
  • Rocky Mountain Movement Disorder Center
    Englewood, Colorado 80113, United States
  • Institute for Neurodegenerative Disorders
    New Haven, Connecticut 06510, United States
  • Georgetown University Hospital
    Washington, District of Columbia 20007, United States
  • Parkinson's Disease and Movement Disorder Center
    Boca Raton, Florida 33486, United States
  • Nova Clinical Research
    Bradenton, Florida 34209, United States
  • University of Florida
    Gainesville, Florida 32608, United States
  • Infinity Clinical Research
    Hollywood, Florida 33024, United States
  • Mayo Clinic Florida
    Jacksonville, Florida 32224, United States
  • Visionary Investigators Network
    Miami, Florida 33133, United States
  • University of Miami
    Miami, Florida 33136, United States
  • Renstar Medical Research
    Ocala, Florida 34470, United States
  • University of South Florida
    Tampa, Florida 33613, United States
  • Charter Research
    Winter Park, Florida 32159, United States
  • Augusta University
    Augusta, Georgia 30912, United States
  • NeuroStudies
    Decatur, Georgia 30033, United States
  • Northwestern Medical Group Neurology Clinic
    Chicago, Illinois 60611, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • SIU Medicine
    Springfield, Illinois 62702, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • University of Maryland, Neurology Ambulatory Center, Maryland Parkinson's Disease and Movement Disorder Center
    Baltimore, Maryland 21201, United States
  • Johns Hopkins University School of Medicine
    Baltimore, Maryland 21287, United States
  • Massachusetts General Hospital Clinical Trials Pharmacy
    Boston, Massachusetts 02114, United States
  • Boston University Medical Center
    Boston, Massachusetts 02118, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • University of Michigan Hospital
    Ann Arbor, Michigan 48109, United States
  • Quest Research Institute
    Farmington Hills, Michigan 48334, United States
  • Henry Ford West Bloomfield Hospital
    West Bloomfield, Michigan 48322, United States
  • Struthers Parkinson's Center
    Golden Valley, Minnesota 55427, United States
  • University of Minnesota Delaware Clinical Research Unit
    Minneapolis, Minnesota 55414, United States
  • Neurology Specialists of Monmouth County
    West Long Branch, New Jersey 07764, United States
  • NYU Langone Medical Center, The Marlene and Paolo Fresco Institute for Parkinson's and Movement Disorders
    New York, New York 10017, United States
  • Neurological Institute, Columbia University Medical Center
    New York, New York 10032, United States
  • UNC CTRC
    Chapel Hill, North Carolina 27599, United States
  • Duke University Medical Center
    Durham, North Carolina 27705, United States
  • Raleigh Neurology
    Raleigh, North Carolina 27607, United States
  • Wake Forest Baptist Health Sciences
    Winston-Salem, North Carolina 27157, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • The Ohio State University Wexner Medical Center
    Columbus, Ohio 43210, United States
  • University of Toledo, Gardner-McMaster Parkinson Center
    Toledo, Ohio 43614, United States
  • The Movement Disorder Clinic of Oklahoma
    Tulsa, Oklahoma 74136, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19107, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • University of Virginia
    Charlottesville, Virginia 22908, United States
  • Booth Gardner Parkinson's Care Center
    Kirkland, Washington 98034, United States
  • Froedtert Hospital
    Milwaukee, Wisconsin 53226, United States
  • Toronto Western Hospital
    Toronto, Ontario M5T 2S8, Canada
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2020 to primary completion in Feb 2023, 35 months.

Of 97 industry-sponsored phase 2 interventional studies under Parkinson Disease, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 33. This study's 35 months is above that.

Counting every sponsor, half of 203 studies reached it within 28 months; a quarter within 16 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2019
First posted
Nov 6, 2019
StartActual
Feb 27, 2020
Primary completionActual
Feb 14, 2023
CompletionActual
Feb 14, 2023
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04154072
Lead sponsor
Neuraly, Inc.
Responsible party
Sponsor
First posted
Nov 6, 2019
Start date
Feb 27, 2020
Primary completion
Feb 14, 2023
Completion
Feb 14, 2023
Last update
Sep 19, 2024

Study contacts

Dan Lee
study director · Neuraly, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegsebrenatide

Start the discussion